Short answer
Solventum (SOLV) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Solventum reported second-quarter 2026 financial results on August 5, 2026.
Solventum 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Solventum reported second-quarter 2026 financial results on August 5, 2026
- Exhibit 99.1 contains the quarter’s financial results and management commentary for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q2 sales $2.209B, up 2.2% reported and 9.5% organically, with growth across every reportable segment
- Adjusted EPS $2.55, up 50.9%, but GAAP operating margin fell 170 bps to 8.2% amid legal and separation costs
- Health Information Systems separation planned, reshaping Solventum toward a focused MedTech portfolio while creating execution and transaction risk
- 2026 guidance raised: organic growth 2.5%-3.0%, adjusted EPS $7.10-$7.20, free cash flow $200M-$300M
- Q2 free cash flow $144M, supported by tax-payment timing and insurance proceeds, while six-month free cash flow remained negative at $129M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Solventum 8-K filings
Get the next SOLV 8-K as it lands
Follow SOLV for push alerts, or ask the research agent what this filing means.